DALLAS, July 24, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring biopharmaceutical company Orexigen Therapeutics Inc. (OREX). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Orexigen Therapeutics Inc. (Nasdaq:OREX) should be of particular interest to other biopharmaceutical companies: VIVUS Inc. (Nasdaq:VVUS), Arena Pharmaceuticals Inc. (Nasdaq:ARNA), Cypress Bioscience Inc. (Nasdaq:CYPB) and Athersys Inc. (Nasdaq:ATHX).
It is available at: http://www.stockpreacher.com/n/OREX
Orexigen Therapeutics Inc. (OREX) is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in phase 3 clinical trials, and Empatic, which is in the later stages of phase 2 clinical development. Both of these product candidates are a combination of generic drugs, designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss.
In the report, the analyst notes:
"On July 20, 2009, OREX announced that all three remaining phase 3 trials evaluating Contrave met their co-primary endpoints. The results from the successfully completed Contrave Obesity Research (COR) program of more than 4,500 patients exceed the FDA categorical efficacy benchmark for clinically significant weight loss. OREX said 48% of obese patients on a higher dose of Contrave lost at least 5% of their body weight, compared with 16.4% of those given a placebo in one trial.
"The Company also has a second weight-loss drug candidate, Empatic, which is in the later stages of phase 2 clinical development. It combines bupropion SR with OREX's proprietary sustained release formulation of zonisamide, an anticonvulsant, which has a number of pharmacologic mechanisms including sodium-channel modulation and enhancement of dopamine and serotonin neurotransmission which result in weight loss."
To read the entire report visit: http://www.stockpreacher.com/n/OREX
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.